Welcome to our dedicated page for Kiniksa Pharmaceuticals International, plc SEC filings (Ticker: KNSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kiniksa Pharmaceuticals International, plc filings document regulatory disclosures for a Nasdaq-listed biopharmaceutical company incorporated in England and Wales. Form 8-K reports cover operating results and financial condition, ARCALYST portfolio execution, investor presentations, and executive appointments or consulting arrangements.
Proxy materials cover annual meeting matters, director elections, executive compensation, shareholder voting procedures, and board governance. The filing record also identifies the company’s Class A ordinary shares, Nasdaq Global Select Market listing, and recurring disclosures tied to its commercial ARCALYST franchise and cardiovascular-focused development portfolio.
Kiniksa Pharmaceuticals International, plc director Barry D. Quart exercised stock options and sold the resulting shares in a planned transaction. On April 6, 2026, he exercised options for 6,901 Class A Ordinary Shares at $14.33 per share, then sold the same 6,901 shares at a weighted average price around $50.00 under a pre-arranged Rule 10b5-1 trading plan. His direct ownership of Class A Ordinary Shares remained at 12,546 shares after the transactions, while his remaining option position decreased by the exercised amount.
Kiniksa Pharmaceuticals (KNSA) reports a Form 144 notice for the intended sale of 20,000 Class A ordinary shares on 04/06/2026, executed as a broker payment for a cashless exercise. The filing also lists recent open-market dispositions by Barry D. Quart, including 12,528 shares on 02/03/2026 and 2,690 shares on 02/12/2026.
Kiniksa Pharmaceuticals submitted a Form 144 reporting 219,591 Class A ordinary shares related to an employee stock option exercise on 04/06/2026. The filing lists $10,979,550.00 in an adjacent field and a reference number of 45,900,637, with broker handling by Charles Schwab & Co.
Kiniksa Pharmaceuticals (KNSA) submitted a Form 144 notice relating to the proposed sale of 2,367 Class A ordinary shares, reported in connection with a restricted stock lapse dated 04/01/2026. The filing lists Charles Schwab & Co., Inc. as the broker and references NASDAQ. A numeric line shows 45,900,637, which appears alongside other securities data in the excerpt.
Kiniksa Pharmaceuticals International, plc Chief Strategy Officer Eben Tessari reported several equity compensation transactions. On April 1, 2026, Tessari received a grant of 33,200 share options for Class A Ordinary Shares at an exercise price of $48.13 per share, expiring on March 31, 2036. The option vests 25% on April 1, 2027, then in 36 monthly installments.
On the same date, Tessari was granted 8,300 Restricted Share Units (RSUs) and 16,600 Performance Share Units (PSUs), each tied to Class A Ordinary Shares. The RSUs vest over four years, with 25% vesting on April 1, 2026 and annually thereafter. The PSUs convert into up to 200% of one share each, based on performance, no later than January 30, 2028.
Also on April 1, 2026, previously granted RSUs vested and were settled into 5,975 Class A Ordinary Shares. Of these, 1,756 shares were withheld at $48.13 per share to satisfy tax obligations, a non‑market disposition, leaving Tessari with 21,250 Class A Ordinary Shares held directly after the transactions. Earlier, on January 15, 2026, Tessari acquired 365 shares at $24.16 per share through the company’s 2018 Employee Share Purchase Plan, an acquisition exempt under Rule 16b‑3(e).
Kiniksa Pharmaceuticals International, plc reported that Chief Financial Officer Mark Ragosa received new equity awards and saw prior awards vest into shares. On April 1, 2026, he was granted 31,150 share options with an exercise price of $48.13 per share, vesting over four years, and expiring in 2036.
He also received 7,800 Restricted Share Units and 15,600 Performance Share Units, each tied to one Class A Ordinary Share, with PSUs payable based on performance and eligible to convert into up to 200% of one share by January 30, 2029. Existing RSUs vested into 5,187 Class A Ordinary Shares, of which 2,510 shares were withheld at $48.13 per share to cover tax obligations, leaving Ragosa holding 14,763 Class A Ordinary Shares directly.
Kiniksa Pharmaceuticals International, plc director and CEO Sanj K. Patel reported equity compensation grants and related share movements. On April 1, 2026, he received a grant of 120,150 share options with an exercise price of $48.13 per share, expiring on March 31, 2036, which vest over time starting April 1, 2026.
He was also granted 30,050 Restricted Share Units (RSUs) vesting over four years from April 1, 2026, and 60,100 Performance Share Units (PSUs), each representing a contingent right to receive Class A Ordinary Shares based on performance and vesting no later than January 30, 2029 at up to 200% of target.
In addition, previously granted RSUs totaling 21,327 units converted into the same number of Class A Ordinary Shares held indirectly through The Patel Family Irrevocable Trust of 2025. Of these, 10,313 shares were disposed of to satisfy tax obligations at $48.13 per share, leaving the trust with 71,014 shares. Separate trusts indirectly hold 109,795 and 51,794 Class A shares, reflecting substantial ongoing ownership.
Kiniksa Pharmaceuticals International, plc reported multiple equity awards and related exercises for its Chief Medical Officer, John F. Paolini, on April 1, 2026. He received a share option for 26,750 Class A Ordinary Shares at an exercise price of $48.13 per share, expiring on March 31, 2036, that vests over time starting April 1, 2026.
He was also granted 6,700 Restricted Share Units and 13,400 Performance Share Units, each linked to Class A Ordinary Shares and subject to four-year time-based or performance-based vesting, with PSUs eligible to convert into up to 200% of one share each by January 30, 2029. In addition, Paolini exercised previously granted RSUs for 5,831 Class A Ordinary Shares, with 2,821 shares withheld at $48.13 per share to cover tax obligations.
Following these transactions, Paolini directly holds 64,334 Class A Ordinary Shares, reflecting routine compensation-related equity activity rather than open-market buying or selling.
Kiniksa Pharmaceuticals International, plc chief operating officer Ross Moat reported multiple equity awards and related share activity. On April 1, 2026, he received a share option grant for 36,950 shares with an exercise price of $48.13 per share, expiring on March 31, 2036.
He was also granted 9,250 Restricted Share Units and 18,500 Performance Share Units, each tied to Class A Ordinary Shares and subject to multi‑year vesting and, for PSUs, performance criteria through January 30, 2029. On the same date, he exercised previously granted RSUs into 5,808 Class A Ordinary Shares, with 1,706 shares withheld at $48.13 per share to cover tax obligations.
Following these transactions, Moat held 14,396 Class A Ordinary Shares directly. Earlier, on January 15, 2026, he acquired 879 Class A Ordinary Shares at $24.16 per share under the company’s 2018 Employee Share Purchase Plan, an acquisition noted as exempt under Rule 16b‑3(e).
Kiniksa Pharmaceuticals International, plc chief accounting officer Michael R. Megna reported multiple equity compensation transactions. On April 1, 2026, he received a share option for 14,600 shares at an exercise price of $48.13, vesting over four years starting April 1, 2026.
He was also granted 3,650 Restricted Share Units and 7,300 Performance Share Units, each tied to Class A Ordinary Shares and subject to multi‑year time- and performance-based vesting. The filing shows RSU exercises converting into 7,564 Class A Ordinary Shares, with 3,205 shares withheld at $48.13 to cover tax obligations.
Following these transactions, Megna directly holds 31,777 Class A Ordinary Shares. Footnotes describe prior participation in the 2018 Employee Share Purchase Plan and detail vesting schedules for the options, RSUs, and PSUs, including potential PSU settlement by January 30, 2029 based on performance.